Virologica Sinica

, Volume 23, Issue 6, pp 473–485

The biology of Kaposi’s sarcoma-associated herpesvirus and the infection of human immunodeficiency virus

Article
  • 34 Downloads

Abstract

Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8), is discovered in 1994 from Kaposi’s sarcoma (KS) lesion of an acquired immunodeficiency syndrome (AIDS) patient. In addition to its association with KS, KSHV has also been implicated as the causative agent of two other AIDS-associated malignancies: primary effusion lymphoma (PEL) and multicentric Castleman’s disease (MCD). KSHV is a complex DNA virus that not only has the ability to promote cellular growth and survival for tumor development, but also can provoke deregulated angiogenesis, inflammation, and modulate the patient’s immune system in favor of tumor growth. As KSHV is a necessary but not sufficient etiological factor for KS, human immunodeficiency virus (HIV) is a very important cofactor. Here we review the basic information about the biology of KSHV, development of pathogenesis and interaction between KSHV and HIV.

Key words

Kaposi sarcoma-associated herpesvirus (KSHV) Biology Pathogenesis HIV 

CLC number

Q786 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ablashi D, Chatlynne L, Cooper H,et al. 1999. Seroprevalence of human herpesvirus-8 (HHV-8) in countries of Southeast Asia compared to the USA, the Caribbean and Africa. Br J Cancer, 81: 893–897.PubMedCrossRefGoogle Scholar
  2. 2.
    Ablashi D V, Chatlynne L G, Whitman J E Jr,et al. 2002. Spectrum of Kaposi’s sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. Clin Microbiol Rev, 15: 439–464.PubMedCrossRefGoogle Scholar
  3. 3.
    Albini A, Paglieri I, Orengo G,et al. 1997. The beta-core fragment of human chorionic gonadotrophin inhibits growth of Kaposi’s sarcoma-derived cells and a new immortalized Kaposi’s sarcoma cell line. AIDS, 11: 713–721.PubMedCrossRefGoogle Scholar
  4. 4.
    Aoki Y, Tosato G. 2003. Targeted inhibition of angiogenic factors in AIDS-related disorders. Curr Drug Targets Infect Disord, 3: 115–128.PubMedCrossRefGoogle Scholar
  5. 5.
    Aoki Y, Tosato G. 2004. HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus (KSHV) infectivity. Blood, 104: 810–814.PubMedCrossRefGoogle Scholar
  6. 6.
    Atkinson J, Edlin B R, Engels E A,et al. 2003. Seroprevalence of human herpesvirus 8 among injection drug users in San Francisco. J Infect Dis, 187: 974–981.PubMedCrossRefGoogle Scholar
  7. 7.
    Bechtel J T, Liang Y, Hvidding J,et al. 2003. Host range of Kaposi’s sarcoma-associated herpesvirus in cultured cells. J Virol, 77: 6474–6481.PubMedCrossRefGoogle Scholar
  8. 8.
    Beral V. 1991. Epidemiology of Kaposi’s sarcoma. Cancer Surv, 10: 5–22.PubMedGoogle Scholar
  9. 9.
    Beral V, Peterman T A, Berkelman R L,et al. 1990. Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection? Lancet, 335: 123–128.PubMedCrossRefGoogle Scholar
  10. 10.
    Blackbourn D J, Lennette E T, Ambroziak J,et al. 1998. Human herpesvirus 8 detection in nasal secretions and saliva. J Infect Dis, 177: 213–216.PubMedCrossRefGoogle Scholar
  11. 11.
    Blackbourn D J, Osmond D, Levy J A,et al. 1999. Increased human herpesvirus 8 seroprevalence in young homosexual men who have multiple sex contacts with different partners. J Infect Dis, 179: 237–239.PubMedCrossRefGoogle Scholar
  12. 12.
    Borkovic S P, Schwartz R A. 1981. Kaposi’s sarcoma presenting in the homosexual man — a new and striking phenomenon! Ariz Med, 38: 902–904.PubMedGoogle Scholar
  13. 13.
    Burysek L, Yeow W S, Lubyova B,et al. 1999. Functional analysis of human herpesvirus 8-encoded viral interferon regulatory factor 1 and its association with cellular interferon regulatory factors and p300. J Virol, 73: 7334–7342.PubMedGoogle Scholar
  14. 14.
    Cannon M J, Dollard S C, Black J B,et al. 2003. Risk factors for Kaposi’s sarcoma in men seropositive for both human herpesvirus 8 and human immunodeficiency virus. AIDS, 17: 215–222.PubMedCrossRefGoogle Scholar
  15. 15.
    Carbone A, Gaidano G. 1997. HHV-8-positive body-cavity-based lymphoma: a novel lymphoma entity. Br J Haematol, 97: 515–522.PubMedCrossRefGoogle Scholar
  16. 16.
    Caselli E, Menegazzi P, Bracci A,et al. 2001. Human herpesvirus-8 (Kaposi’s sarcoma-associated herpesvirus) ORF50 interacts synergistically with the tat gene product in transactivating the human immunodeficiency virus type 1 LTR. J Gen Virol, 82: 1965–1970.PubMedGoogle Scholar
  17. 17.
    Caselli E, Galvan M, Santoni F,et al. 2003. Human herpesvirus-8 (Kaposi’s sarcoma-associated virus) ORF50 increases in vitro cell susceptibility to human immunodeficiency virus type 1 infection. J Gen Virol, 84: 1123–1131.PubMedCrossRefGoogle Scholar
  18. 18.
    Caselli E, Galvan M, Cassai E,et al. 2003. Transient expression of human herpesvirus-8 (Kaposi’s sarcoma-associated herpesvirus) ORF50 enhances HIV-1 replication. Intervirology, 46: 141–149.PubMedCrossRefGoogle Scholar
  19. 19.
    Caselli E, Galvan M, Cassai E,et al. 2005. Human herpesvirus 8 enhances human immunodeficiency virus replication in acutely infected cells and induces reactivation in latently infected cells. Blood, 106: 2790–2797.PubMedCrossRefGoogle Scholar
  20. 20.
    Cathomas G, McGandy C E, Terracciano L M,et al. 1996. Detection of herpesvirus-like DNA by nested PCR on archival skin biopsy specimens of various forms of Kaposi sarcoma. J Clin Pathol, 49: 631–633.PubMedCrossRefGoogle Scholar
  21. 21.
    Cesarman E, Chang Y, Moore P S,et al. 1995. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med, 332: 1186–1191.PubMedCrossRefGoogle Scholar
  22. 22.
    Cesarman E. 2002. The role of Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV-8) in lymphoproliferative diseases. Recent Results Cancer Res, 159: 27–37.PubMedGoogle Scholar
  23. 23.
    Chang Y, Cesarman E, Pessin M S,et al. 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science, 266: 1865–1869.PubMedCrossRefGoogle Scholar
  24. 24.
    Chatlynne L G, Ablashi D V. 1999. Seroepidemiology of Kaposi’s sarcoma-associated herpesvirus (KSHV). Semin Cancer Biol, 9: 175–185.PubMedCrossRefGoogle Scholar
  25. 25.
    Chatlynne L G, Lapps W, Handy M,et al. 1998. Detection and titration of human herpesvirus-8-specific antibodies in sera from blood donors, acquired immuno-deficiency syndrome patients, and Kaposi’s sarcoma patients using a whole virus enzyme-linked immunosorbent assay. Blood, 92: 53–58.PubMedGoogle Scholar
  26. 26.
    Cheng E H, Nicholas J, Bellows D S,et al. 1997. A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. Proc Natl Acad Sci U S A, 94: 690–694.PubMedCrossRefGoogle Scholar
  27. 27.
    Child E S, Mann D J. 2001. Novel properties of the cyclin encoded by Human Herpesvirus 8 that facilitate exit from quiescence. Oncogene, 20: 3311–3322.PubMedCrossRefGoogle Scholar
  28. 28.
    Couty J P, Geras-Raaka E, Weksler B B,et al. 2001. Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor signals through multiple pathways in endothelial cells. J Biol Chem, 276: 33805–33811.PubMedCrossRefGoogle Scholar
  29. 29.
    de-The G, Bestetti G, van Beveren M,et al. 1999. Prevalence of human herpesvirus 8 infection before the acquired immunodeficiency disease syndrome-related epidemic of Kaposi’s sarcoma in East Africa. J Natl Cancer Inst, 91: 1888–1889.PubMedCrossRefGoogle Scholar
  30. 30.
    Dedicoat M, Newton R, Alkharsah K R,et al. 2004. Mother-to-child transmission of human herpesvirus-8 in South Africa. J Infect Dis, 190: 1068–1075.PubMedCrossRefGoogle Scholar
  31. 31.
    Duus K M, Lentchitsky V, Wagenaar T,et al. 2004. Wild-type Kaposi’s sarcoma-associated herpesvirus isolated from the oropharynx of immune-competent individuals has tropism for cultured oral epithelial cells. J Virol, 78: 4074–4084.PubMedCrossRefGoogle Scholar
  32. 32.
    Enbom M, Sheldon J, Lennette E,et al. 2000. Antibodies to human herpesvirus 8 latent and lytic antigens in blood donors and potential high-risk groups in Sweden: variable frequencies found in a multicenter serological study. J Med Virol, 62: 498–504.PubMedCrossRefGoogle Scholar
  33. 33.
    Engels E A, Sinclair M D, Biggar R J,et al. 2000. Latent class analysis of human herpesvirus 8 assay performance and infection prevalence in sub-saharan Africa and Malta. Int J Cancer, 88: 1003–1008.PubMedCrossRefGoogle Scholar
  34. 34.
    Ensoli B, Sgadari C, Barillari G,et al. 2001. Biology of Kaposi’s sarcoma. Eur J Cancer, 37: 1251–1269.PubMedCrossRefGoogle Scholar
  35. 35.
    Ensoli B, Sturzl M, Monini P. 2001. Reactivation and role of HHV-8 in Kaposi’s sarcoma initiation. Adv Cancer Res, 81: 161–200.PubMedCrossRefGoogle Scholar
  36. 36.
    Field N, Low W, Daniels M,et al. 2003. KSHV vFLIP binds to IKK-gamma to activate IKK. J Cell Sci, 116: 3721–3728.PubMedCrossRefGoogle Scholar
  37. 37.
    Friborg J Jr, Kong W, Hottiger M O,et al. 1999. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature, 402: 889–894.PubMedGoogle Scholar
  38. 38.
    Friedman-Kien A E. 1981. Disseminated Kaposi’s sarcoma syndrome in young homosexual men. J Am Acad Dermatol, 5: 468–471.PubMedCrossRefGoogle Scholar
  39. 39.
    Gambus G, Bourboulia D, Esteve A,et al. 2001. Prevalence and distribution of HHV-8 in different subpopulations, with and without HIV infection, in Spain. AIDS, 15: 1167–1174.PubMedCrossRefGoogle Scholar
  40. 40.
    Gao S J, Boshoff C, Jayachandra S,et al. 1997. KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. Oncogene, 15: 1979–1985.PubMedCrossRefGoogle Scholar
  41. 41.
    Gao S J, Kingsley L, Li M,et al. 1996. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi’s sarcoma. Nat Med, 2: 925–928.PubMedCrossRefGoogle Scholar
  42. 42.
    Gessain A, Mauclere P, van Beveren M,et al. 1999. Human herpesvirus 8 primary infection occurs during childhood in Cameroon, Central Africa. Int J Cancer, 81: 189–192.PubMedCrossRefGoogle Scholar
  43. 43.
    Giraldo G, Beth E, Haguenau F. 1972. Herpes-type virus particles in tissue culture of Kaposi’s sarcoma from different geographic regions. J Natl Cancer Inst, 49: 1509–1526.PubMedGoogle Scholar
  44. 44.
    Goedert J J, Cote T R, Virgo P,et al. 1998. Spectrum of AIDS-associated malignant disorders. Lancet, 351: 1833–1839.PubMedCrossRefGoogle Scholar
  45. 45.
    Gottlieb G J, Ragaz A, Vogel J V,et al. 1981. A preliminary communication on extensively disseminated Kaposi’s sarcoma in young homosexual men. Am J Dermatopathol, 3: 111–114.PubMedCrossRefGoogle Scholar
  46. 46.
    Grossman Z, Iscovich J, Schwartz F,et al. 2002. Absence of Kaposi sarcoma among Ethiopian immigrants to Israel despite high seroprevalence of human herpesvirus8. Mayo Clin Proc, 77: 905–909.PubMedCrossRefGoogle Scholar
  47. 47.
    Guasparri I, Keller S A, Cesarman E. 2004. KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med, 199: 993–1003.PubMedCrossRefGoogle Scholar
  48. 48.
    Guo H G, Pati S, Sadowska M,et al. 2004. Tumorigenesis by human herpesvirus 8 vGPCR is accelerated by human immunodeficiency virus type 1 Tat. J Virol, 78: 9336–9342.PubMedCrossRefGoogle Scholar
  49. 49.
    Gwack Y, Hwang S, Byun H,et al. 2001. Kaposi’s sarcoma-associated herpesvirus open reading frame 50 represses p53-induced transcriptional activity and apoptosis. J Virol, 75: 6245–6248.PubMedCrossRefGoogle Scholar
  50. 50.
    Hengge U R, Ruzicka T, Tyring S K,et al. 2002. Update on Kaposi’s sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman’s disease, and pleural effusion lymphoma. Lancet Infect Dis, 2: 344–352.PubMedCrossRefGoogle Scholar
  51. 51.
    Hideshima T, Chauhan D, Teoh G,et al. 2000. Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi’s sarcoma-associated herpes virus-encoded viral interleukin 6. Clin Cancer Res, 6: 1180–1189.PubMedGoogle Scholar
  52. 52.
    Huang L M, Chao M F, Chen M Y,et al. 2001. Reciprocal regulatory interaction between human herpesvirus 8 and human immunodeficiency virus type 1. J Biol Chem, 276: 13427–13432.PubMedCrossRefGoogle Scholar
  53. 53.
    Hymes K B, Cheung T, Greene J B,et al. 1981. Kaposi’s sarcoma in homosexual men-a report of eight cases. Lancet, 2: 598–600.PubMedCrossRefGoogle Scholar
  54. 54.
    Hyun T S, Subramanian C, Cotter M A 2nd,et al. 2001. Latency-associated nuclear antigen encoded by Kaposi’s sarcoma-associated herpesvirus interacts with Tat and activates the long terminal repeat of human immunodeficiency virus type 1 in human cells. J Virol, 75: 8761–8771.PubMedCrossRefGoogle Scholar
  55. 55.
    Iscovich J, Boffetta P, Franceschi S,et al. 2000. Classic kaposi sarcoma: epidemiology and risk factors. Cancer, 88: 500–517.PubMedCrossRefGoogle Scholar
  56. 56.
    Jacobson L P, Jenkins F J, Springer G,et al. 2000. Interaction of human immunodeficiency virus type 1 and human herpesvirus type 8 infections on the incidence of Kaposi’s sarcoma. J Infect Dis, 181: 1940–1949.PubMedCrossRefGoogle Scholar
  57. 57.
    Juhasz A, Remenyik E, Konya J,et al. 2001. Prevalence and age distribution of human herpesvirus-8 specific antibodies in Hungarian blood donors. J Med Virol, 64: 526–530.PubMedCrossRefGoogle Scholar
  58. 58.
    Juhasz I, Albelda S M, Elder D E,et al. 1993. Growth and invasion of human melanomas in human skin grafted to immunodeficient mice. Am J Pathol, 143: 528–537.PubMedGoogle Scholar
  59. 59.
    Kaaya S F, Leshabari M T, Mbwambo J K. 1998. Risk behaviors and vulnerability to HIV infection among Tanzanian youth. J Health Popul Dev Ctries, 1: 51–60.PubMedGoogle Scholar
  60. 60.
    Kaposi M. 1872. Idiopathisches multiples Pigmentsarkom der Haut. Arch Dermatol Syph, 4: 265–273.CrossRefGoogle Scholar
  61. 61.
    Kirchhoff S, Sebens T, Baumann S,et al. 2002. Viral IFN-regulatory factors inhibit activation-induced cell death via two positive regulatory IFN-regulatory factor 1-dependent domains in the CD95 ligand promoter. J Immunol, 168: 1226–1234.PubMedGoogle Scholar
  62. 62.
    Lang M E, Lottersberger C, Roth B,et al. 1997. Induction of apoptosis in Kaposi’s sarcoma spindle cell cultures by the subunits of human chorionic gonadotropin. AIDS, 11: 1333–1340.PubMedGoogle Scholar
  63. 63.
    Lennette E T, Blackbourn D J, Levy J A. 1996. Antibodies to human herpesvirus type 8 in the general population and in Kaposi’s sarcoma patients. Lancet, 348: 858–861.PubMedCrossRefGoogle Scholar
  64. 64.
    Li M, Lee H, Yoon D W,et al. 1997. Kaposi’s sarcoma-associated herpesvirus encodes a functional cyclin. J Virol, 71: 1984–1991.PubMedGoogle Scholar
  65. 65.
    Liu L, Eby M T, Rathore N,et al. 2002. The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the Ikappa B kinase complex. J Biol Chem, 277: 13745–13751.PubMedCrossRefGoogle Scholar
  66. 66.
    Lubyova B, Pitha P M. 2000. Characterization of a novel human herpesvirus 8-encoded protein, vIRF-3, that shows homology to viral and cellular interferon regulatory factors. J Virol, 74: 8194–8201.PubMedCrossRefGoogle Scholar
  67. 67.
    Martin J N, Ganem D E, Osmond D H,et al. 1998. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med, 338: 948–954.PubMedCrossRefGoogle Scholar
  68. 68.
    Martin R W 3rd, Hood A F, Farmer E R. 1993. Kaposi sarcoma. Medicine (Baltimore), 72: 245–261.Google Scholar
  69. 69.
    Matta H, Chaudhary P M. 2004. Activation of alternative NF-kappa B pathway by human herpes virus 8-encoded Fas-associated death domain-like IL-1 beta-converting enzyme inhibitory protein (vFLIP). Proc Natl Acad Sci U S A, 101: 9399–9404.PubMedCrossRefGoogle Scholar
  70. 70.
    Mayama S, Cuevas L E, Sheldon J,et al. 1998. Prevalence and transmission of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in Ugandan children and adolescents. Int J Cancer, 77: 817–820.PubMedCrossRefGoogle Scholar
  71. 71.
    Mbulaiteye S M, Biggar R J, Goedert J J,et al. 2003. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr, 32: 527–533.PubMedCrossRefGoogle Scholar
  72. 72.
    Mbulaiteye S M, Pfeiffer R M, Whitby D,et al. 2003. Human herpesvirus 8 infection within families in rural Tanzania. J Infect Dis, 187: 1780–1785.PubMedCrossRefGoogle Scholar
  73. 73.
    Mendez J C, Procop G W, Espy M J,et al. 1999. Relationship of HHV8 replication and Kaposi’s sarcoma after solid organ transplantation. Transplantation, 67: 1200–1201.PubMedCrossRefGoogle Scholar
  74. 74.
    Merat R, Amara A, Lebbe C,et al. 2002. HIV-1 infection of primary effusion lymphoma cell line triggers Kaposi’s sarcoma-associated herpesvirus (KSHV) reactivation. Int J Cancer, 97: 791–795.PubMedCrossRefGoogle Scholar
  75. 75.
    Mercader M, Taddeo B, Panella J R,et al. 2000. Induction of HHV-8 lytic cycle replication by inflammatory cytokines produced by HIV-1-infected T cells. Am J Pathol, 156: 1961–1971.PubMedGoogle Scholar
  76. 76.
    Mercader M, Nickoloff B J, Foreman K E. 2001. Induction of human immunodeficiency virus 1 replication by human herpesvirus 8. Arch Pathol Lab Med, 125: 785–789.PubMedGoogle Scholar
  77. 77.
    Molden J, Chang Y, You Y,et al. 1997. A Kaposi’s sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J Biol Chem, 272: 19625–19631.PubMedCrossRefGoogle Scholar
  78. 78.
    Montaner S, Sodhi A, Pece S,et al. 2001. The Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B. Cancer Res, 61: 2641–2648.PubMedGoogle Scholar
  79. 79.
    Moore P S, Chang Y. 2001. Molecular virology of Kaposi’s sarcoma-associated herpesvirus. Philos Trans R Soc Lond B Biol Sci, 356: 499–516.PubMedCrossRefGoogle Scholar
  80. 80.
    Moore P S, Kingsley L A, Holmberg S D,et al. 1996. Kaposi’s sarcoma-associated herpesvirus infection prior to onset of Kaposi’s sarcoma. AIDS, 10: 175–180.PubMedCrossRefGoogle Scholar
  81. 81.
    Moore P S, Gao S J, Dominguez G,et al. 1996. Primary characterization of a herpesvirus agent associated with Kaposi’s sarcomae. J Virol, 70: 549–558.PubMedGoogle Scholar
  82. 82.
    Munshi N, Ganju R K, Avraham S,et al. 1999. Kaposi’s sarcoma-associated herpesvirus-encoded G protein-coupled receptor activation of c-jun amino-terminal kinase/stress-activated protein kinase and lyn kinase is mediated by related adhesion focal tyrosine kinase/proline-rich tyrosine kinase 2. J Biol Chem, 274: 31863–31867.PubMedCrossRefGoogle Scholar
  83. 83.
    Nador R G, Cesarman E, Chadburn A,et al. 1996. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood, 88: 645–656.PubMedGoogle Scholar
  84. 84.
    Nakamura H, Li M, Zarycki J,et al. 2001. Inhibition of p53 tumor suppressor by viral interferon regulatory factor. J Virol, 75: 7572–7582.PubMedCrossRefGoogle Scholar
  85. 85.
    Neipel F, Albrecht J C, Fleckenstein B. 1997. Cell-homologous genes in the Kaposi’s sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity? J Virol, 71: 4187–4192.PubMedGoogle Scholar
  86. 86.
    O’Brien T R, Kedes D, Ganem D,et al. 1999. Evidence for concurrent epidemics of human herpesvirus 8 and human immunodeficiency virus type 1 in US homosexual men: rates, risk factors, and relationship to Kaposi’s sarcoma. J Infect Dis, 180: 1010–1017.PubMedCrossRefGoogle Scholar
  87. 87.
    Oettle A G. 1962. Geographical and racial differences in the frequency of Kaposi’s sarcoma as evidence of environmental or genetic causes. Acta Unio Int Contra Cancrum, 18: 330–363.PubMedGoogle Scholar
  88. 88.
    Olsen S J, Chang Y, Moore P S,et al. 1998. Increasing Kaposi’s sarcoma-associated herpesvirus seroprevalence with age in a highly Kaposi’s sarcoma endemic region, Zambia in 1985. AIDS, 12: 1921–1925.PubMedCrossRefGoogle Scholar
  89. 89.
    Osborne J, Moore P S, Chang Y. 1999. KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways. Hum Immunol, 60: 921–927.PubMedCrossRefGoogle Scholar
  90. 90.
    Pati S, Cavrois M, Guo H G,et al. 2001. Activation of NF-kappaB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposi’s sarcoma pathogenesis. J Virol, 75: 8660–8673.PubMedCrossRefGoogle Scholar
  91. 91.
    Pauk J, Huang M L, Brodie S J,et al. 2000. Mucosal shedding of human herpesvirus 8 in men. N Engl J Med, 343: 1369–1377.PubMedCrossRefGoogle Scholar
  92. 92.
    Plancoulaine S, Abel L, van Beveren M,et al. 2000. Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population. Lancet, 356: 1062–1065.PubMedCrossRefGoogle Scholar
  93. 93.
    Plancoulaine S, Abel L, Tregouet D,et al. 2004. Respective roles of serological status and blood specific antihuman herpesvirus 8 antibody levels in human herpesvirus 8 intrafamilial transmission in a highly endemic area. Cancer Res, 64: 8782–8787.PubMedCrossRefGoogle Scholar
  94. 94.
    Preiser W, Szep N I, Lang D,et al. 2001. Kaposi’s sarcoma-associated herpesvirus seroprevalence in selected german patients: evaluation by different test systems. Med Microbiol Immunol, 190: 121–127.PubMedGoogle Scholar
  95. 95.
    Rabkin C S, Janz S, Lash A,et al. 1997. Monoclonal origin of multicentric Kaposi’s sarcoma lesions. N Engl J Med, 336: 988–993.PubMedCrossRefGoogle Scholar
  96. 96.
    Radkov S A, Kellam P, Boshoff C. 2000. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med, 6: 1121–1127.PubMedCrossRefGoogle Scholar
  97. 97.
    Regamey N, Cathomas G, Schwager M,et al. 1998. High human herpesvirus 8 seroprevalence in the homosexual population in Switzerland. J Clin Microbiol, 36: 1784–1786.PubMedGoogle Scholar
  98. 98.
    Renne R, Blackbourn D, Whitby D,et al. 1998. Limited transmission of Kaposi’s sarcoma-associated herpesvirus in cultured cells. J Virol, 72: 5182–5188.PubMedGoogle Scholar
  99. 99.
    Renne R, Lagunoff M, Zhong W,et al. 1996. The size and conformation of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) DNA in infected cells and virions. J Virol, 70: 8151–8154.PubMedGoogle Scholar
  100. 100.
    Rivas C, Thlick A E, Parravicini C,et al. 2001. Kaposi’s sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J Virol, 75: 429–438.PubMedCrossRefGoogle Scholar
  101. 101.
    Russo J J, Bohenzky R A, Chien M C,et al. 1996. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A, 93: 14862–14867.PubMedCrossRefGoogle Scholar
  102. 102.
    Samaniego F, Young D, Grimes C,et al. 2002. Vascular endothelial growth factor and Kaposi’s sarcoma cells in human skin grafts. Cell Growth Differ, 13: 387–395.PubMedGoogle Scholar
  103. 103.
    Sarek G, Jarviluoma A, Ojala P M. 2006. KSHV viral cyclin inactivates p27KIP1 through Ser10 and Thr187 phosphorylation in proliferating primary effusion lymphomas. Blood, 107: 725–732.PubMedCrossRefGoogle Scholar
  104. 104.
    Sarid R, Flore O, Bohenzky R A,et al. 1998. Transcription mapping of the Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). J Virol, 72: 1005–1012.PubMedGoogle Scholar
  105. 105.
    Sarid R, Sato T, Bohenzky R A,et al. 1997. Kaposi’s sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nat Med, 3: 293–298.PubMedCrossRefGoogle Scholar
  106. 106.
    Schulz T F. 2000. KSHV (HHV8) infection. J Infect, 41: 125–129.PubMedCrossRefGoogle Scholar
  107. 107.
    Schwarz M, Murphy P M. 2001. Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor cons-titutively activates NF-kappa B and induces proinflammatory cytokine and chemokine production via a C-terminal signaling determinant. J Immunol, 167: 505–513.PubMedGoogle Scholar
  108. 108.
    Seo T, Lee D, Shim Y S,et al. 2002. Viral interferon regulatory factor 1 of Kaposi’s sarcoma-associated herpesvirus interacts with a cell death regulator, GRIM19, and inhibits interferon/retinoic acid-induced cell death. J Virol, 76: 8797–8807.PubMedCrossRefGoogle Scholar
  109. 109.
    Seo T, Park J, Lee D,et al. 2001. Viral interferon regulatory factor 1 of Kaposi’s sarcoma-associated herpesvirus binds to p53 and represses p53-dependent transcription and apoptosis. J Virol, 75: 6193–6198.PubMedCrossRefGoogle Scholar
  110. 110.
    Shin Y C, Nakamura H, Liang X,et al. 2006. Inhibition of the ATM/p53 signal transduction pathway by Kaposi’s sarcoma-associated herpesvirus interferon regulatory factor 1. J Virol, 80: 2257–2266.PubMedCrossRefGoogle Scholar
  111. 111.
    Siegal F P, Lopez C, Hammer G S,et al. 1981. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med, 305: 1439–1444.PubMedGoogle Scholar
  112. 112.
    Sitas F, Carrara H, Beral V,et al. 1999. Antibodies against human herpesvirus 8 in black South African patients with cancer. N Engl J Med, 340: 1863–1871.PubMedCrossRefGoogle Scholar
  113. 113.
    Smit M J, Verzijl D, Casarosa P,et al. 2002. Kaposi’s sarcoma-associated herpesvirus-encoded G protein-coupled receptor ORF74 constitutively activates p44/p42 MAPK and Akt via G(i) and phospholipase C-dependent signaling pathways. J Virol, 76: 1744–1752.PubMedCrossRefGoogle Scholar
  114. 114.
    Soulier J, Grollet L, Oksenhendler E,et al. 1995. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood, 86: 1276–1280.PubMedGoogle Scholar
  115. 115.
    Sternbach G, Varon J. 1995. Moritz Kaposi: idiopathic pigmented sarcoma of the skin. J Emerg Med, 13: 671–674.PubMedCrossRefGoogle Scholar
  116. 116.
    Sturzl M, Hohenadl C, Zietz C,et al. 1999. Expression of K13/v-FLIP gene of human herpesvirus 8 and apoptosis in Kaposi’s sarcoma spindle cells. J Natl Cancer Inst, 91: 1725–1733.PubMedCrossRefGoogle Scholar
  117. 117.
    Sun Q, Matta H, Chaudhary P M. 2005. Kaposi’s sarcoma associated herpes virus-encoded viral FLICE inhibitory protein activates transcription from HIV-1 Long Terminal Repeat via the classical NF-kappaB pathway and functionally cooperates with Tat. Retrovirology, 2: 9.PubMedCrossRefGoogle Scholar
  118. 118.
    Wan X, Wang H, Nicholas J. 1999. Human herpesvirus 8 interleukin-6 (vIL-6) signals through gp130 but has structural and receptor-binding properties distinct from those of human IL-6. J Virol, 73: 8268–8278.PubMedGoogle Scholar
  119. 119.
    West J T, Wood C. 2003. The role of Kaposi’s sarcoma-associated herpesvirus/human herpesvirus-8 regulator of transcription activation (RTA) in control of gene expression. Oncogene, 22: 5150–5163.PubMedCrossRefGoogle Scholar
  120. 120.
    Whitby D, Howard M R, Tenant-Flowers M,et al. 1995. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi’s sarcoma. Lancet, 346: 799–802.PubMedCrossRefGoogle Scholar
  121. 121.
    Whitby D, Luppi M, Barozzi P,et al. 1998. Human herpesvirus 8 seroprevalence in blood donors and lymphoma patients from different regions of Italy. J Natl Cancer Inst, 90: 395–397.PubMedCrossRefGoogle Scholar
  122. 122.
    Zeng Y, Zhang X, Huang Z,et al. 2007. Intracellular Tat of human immunodeficiency virus type 1 activates lytic cycle replication of Kaposi’s sarcoma-associated herpesvirus: role of JAK/STAT signaling. J Virol, 81: 2401–2417.PubMedCrossRefGoogle Scholar
  123. 123.
    Zhu F X, Chong J M, Wu L,et al. 2005. Virion proteins of Kaposi’s sarcoma-associated herpesvirus. J Virol, 79: 800–811.PubMedCrossRefGoogle Scholar
  124. 124.
    Ziegler J L, Newton R, Katongole-Mbidde E,et al. 1997. Risk factors for Kaposi’s sarcoma in HIV-positive subjects in Uganda. AIDS, 11: 1619–1626. VIROLOGICA SINICA, December 2008, 23 (6):486–495PubMedCrossRefGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS and Springer-Verlag GmbH 2008

Authors and Affiliations

  1. 1.Laboratory of Molecular Virology, Department of Microbiology and ImmunologyNanjing Medical UniversityNanjingChina

Personalised recommendations